New Delhi: Max Healthcare announced the launch of chimeric antigen receptor (CAR)-T cell therapy at its hospital in Delhi-NCR.
The sourcing of CAR-T cells for this therapy is done in collaboration with ImmunoACT, an IIT Bombay-incubated company. Last month, ImmunoACT received the Central Drugs Standard Control Organisation’s (CDSCO) marketing authorisation approval for its CAR-T cell therapy product for relapsed/refractory B-cell lymphomas and leukaemia in India.
Speaking on the launch Dr Harit K Chaturvedi, Chairman, Max Institute of Cancer Care said, “The introduction of CAR-T cell therapy at Max Healthcare marks a significant leap in our commitment to providing cutting-edge care for cancer patients. This innovative approach reflects our continuous endeavour to push the boundaries of cancer treatment, offering patients the most advanced therapeutic options available.”
Also known as a ‘living drug’, this therapy provides enduring benefits and is recommended for those not able to undergo a stem cell transplant or post-transplant relapse. Compared to conventional therapies, this requires a brief, single-infusion treatment, enhancing the quality of life for many patients with an average of two weeks of in-patient care.
Emphasising the significance of this launch, Dr EshaKaul, Director – Haemato-Oncology/ Bone Marrow Transplant, Max Super Speciality Hospital, Vaishali said, “Through this groundbreaking therapy, we are reinforcing our commitment to delivering personalised and effective solutions that align with the evolving healthcare landscape, contributing to the overall well-being and positive outcomes for those under our care.
Shirish Arya, Co-founder, and Director – Strategy & Business Development, ImmunoACT said, “Patients in India and countries with limited resources will now have access to this life-saving drug at an affordable cost. The indigenously-developed product will put the country on the world map of advanced cell-and-gene therapies.”
